



AF/1648

Please type a plus sign (+) inside this box → ☐PTO/SB/21 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application</b>	09/055,744	
	<b>Filing Date</b>	April 7, 1998	
	<b>First Named</b>	Charles D.Y. Sia	
	<b>Group Art Unit</b>	1648	
	<b>Examiner Name</b>	Robert D. Budens	
<b>Total Number of Pages in This Submission</b>	7	<b>Attorney Docket Number</b>	1038-746 MIS

ENCLOSURES <i>(check all that apply)</i>		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i>	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence	<input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<b>Remarks</b>	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

<b>Firm or Individual name</b>	Michael I. Stewart (Reg. No. 24,93)
<b>Signature</b>	<i>Michael I. Stewart</i>
<b>Date</b>	March 15, 2002

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:	
<b>Typed or printed name</b>	
<b>Signature</b>	<b>Date</b>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

#24  
Amend. Done  
3/23/02

Applicant : Charles D.Y. Sia, et al.  
Appl'n. No. : 09/055,744  
Filed : April 7, 1998  
Title : HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES  
Grp./A.U. : 1648  
Examiner : Robert D. Budens  
Docket No. : 1038-746 MIS:jb  
Date : March 15, 2002

**BY COURIER**

The Commissioner of Patents  
and Trademarks,  
Box AF  
Washington, D.C. 20231,  
U.S.A.

**AMENDMENT AFTER FINAL ACTION**  
**(Response Under 37 CFR 1.116 - Expedited Procedure)**

Sir:

In response to the Office Action of December 19, 2001, please amend the above-identified application as follows:

**In the Claims:**

Claims 1, 10 and 13 have been amended as follows:

1. (Twice Amended) A method of generating an HIV-specific cytotoxic T-cell (CTL) response in a host possessing MHC class I HLA A2 molecules, which comprises:  
administering to the host a T-helper molecule to prime T-helper cells of the immune system of the host, and  
subsequently administering to the host a mixture of said T-helper molecule and a T-cell inducing HIV molecule capable of binding to MHC class I HLA A2 molecules to generate an HIV-specific T-cell response in the host.

Do Not Enter  
4/2/02